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Background: Improvements in immunosuppression have resulted in long life expectancy of kidney transplants.
Unfortunately, the incidence of post-transplant malignancy (PTM) is increasing. The aim of this study was to
evaluate the nature and stage-specific prognosis of post-transplant breast cancer (PTBC) compared with breast
cancer in the general population, and to suggest optimal treatment strategies.
Methods: A database of 2,139 consecutive kidney transplant patients was reviewed;11 of the patients developed
breast cancer. These 11 PTBC cases underwent operations between 1999 and 2011. Next, 2,554 breast cancer
patients treated in the same period were reviewed. Kaplan–Meier curves and the log-rank test were used to assess
stage-specific survival of breast cancer in our hospital.
Results: In total, 142 cases experienced post-transplant malignancy (PTM; 6.6%) and 11 (0.5%) developed PTBC. No
one required an adjusted dose of immunosuppressive agent. Two stage III patients died. For all breast cancer
patients, 5-year survival by stage was 97.7% for stage I, 92.9% for stage II, 78.6% for stage III, and 49.9% for stage IV.
The 5-year survival for expected stage III-specific survival was 66.7% and no significant statistical difference was seen
compared to that of the total breast cancer patients (P = 0.213).
Conclusions: The prognosis of PTBC was comparable to that of the general population. These results suggest that
the use of immunosuppressants per se does not adversely affect breast cancer.
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As immunosuppressive agents have continued to improve,
the lifespans of recipients after renal transplantation have
been prolonged. Unfortunately, immunosuppressed renal
transplant patients have a higher incidence of carcinomas
than the general population [1-3].
The treatment of breast cancer in the transplant
population is somewhat complicated by factors such as
determining the correct dose of immunosuppressant,
survival of transplant grafts, and doses of adjuvant
chemotherapy. However, there is limited information
regarding the treatment of this disease. Although the
number of cases was small, we sought to evaluate the
nature and prognosis of post-transplant breast cancer
(PTBC) and to suggest optimal strategies based on our
experience and a review of the literature.* Correspondence: bjsong@catholic.ac.kr
Department of Surgery, Catholic University of Korea, College of Medicine,
Seoul, Republic of Korea
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Patient cohort
A total of 2,139 consecutive patients with chronic renal
failure underwent kidney transplantation in our hospital
between March 1999 and December 2011. All clinical and
pathological features of the recipients of renal transplants
were collected from the database of Seoul St. Mary’s
Hospital. Among these patients, 142 experienced post-
transplant malignancy (PTM) and 11 were diagnosed with
post-transplant breast cancer (PTBC). These 11 patients
underwent operations between 1999 and 2011.
In the meantime, 2,554 patients were diagnosed with
invasive breast cancer and underwent operations between
1999 and 2011. Exclusion criteria were patients with no
pathological TNM status due to mass excision at an outside
hospital, in situ breast cancer, previous breast cancer
surgery, prior radiation, distant metastasis, and prior
axillary surgery. Thus, in total, 1,722 patients were
reviewed. All protocols were approved by the institutionaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Comparison of demographics
KT PTM PTBC
n 2,139 142 11
Age, years (mean ± SD) 51.0 ± 17.1 54.7 ± 20.7 35 ± 8.0
Male: female ratio 65.0 : 35.0 54.9 : 45.1 9.1 : 90.9
Mean time of occurrence,
months (mean ± SD)
110.7 ± 71.3 136.5 ± 101.2
KT: kidney transplantation; PTBC: post-transplant breast cancer; PTM:
post-transplant malignancy.
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University of Korea (KC12RISI0626) and met the guide-
lines of the responsible governmental agency.Statistical analyses
The primary endpoint was death (overall survival). All
patients who underwent an operation according to the
standard protocols used at our hospital were treated with
adjuvant chemotherapy and/or radiotherapy. Overall
survival (OS) was defined as the time from the diagnosis of
breast cancer to death. Statistical significance was deter-
mined using the chi-squared test. Survival rates were calcu-
lated by the Kaplan–Meier method and compared with the
log-rank test, and then by stage of disease. P values < 0.05
were deemed to indicate statistical significance.Results
Overall, 142 subjects experienced post-transplant ma-
lignancy (PTM; 6.6%). All cases were confirmed both
clinically and histologically. Of the 142 PTM patients,
11 (0.5%) developed PTBC. These 11 patients underwent
operations between 1999 and 2011. The mean ages of the
PTM and PTBC cases were 54.7 ± 20.7 and 35 ± 8.0 years,
respectively. The mean times before the occurrence ofTable 2 Clinicopathological features of the 11 PTBC patients
Patient Age Duration to
diagnosis
(months)
Procedure Stage Positivity of
hormone recep
1 42 42 SM with SLNB I +
2 49 6 MRM I +
3 28 127 MRM III -
4 24 134 Excision biopsy Unknown -
5 40 177 SM with SLNB I -
6 43 181 MRM III -
7 35 89 MRM III -
8 28 354 SM with SLNB II +
9 29 176 WE with SLNB I +
10 29 208 SM with SLNB I -
11 38 8 MRM III +
aC: cyclophosphamide, M: methotrexate, F: 5-fluorouracil, A: adriamycin, T: taxotere.
MRM: modified radical mastectomy; SLNB: sentinel lymph node biopsy;SM: simple mcancer were 110.7 ± 71.3 and 136.5 ± 101.2 months,
respectively (Table 1).
Of the 11 PTBC patients, 9 patients take 200 mgNeoral
capsule(cyclosporine capsules) per day. One patient takes
azathioprine (patient number 9) and one other patient
takes FK506 (tacrolimus) (patient number 1).
Unlike other studies [4-7], gastrointestinal cancers,
such as stomach and colon cancer, developed in 39 of
the 142 PTM patients (27.5%) and were the most
frequent. Other cancers were lymphomas (14.8%), uro-
genital cancers (12%), gynecological cancers (8.5%), and
breast cancer (7.7%).
Table 2 shows the clinicopathological features of the
11 PTBC patients. The median age at diagnosis of breast
cancer was 49 years. Five patients underwent modified
radical mastectomies, four had simple mastectomies
with sentinel lymph node biopsies, one had a wide exci-
sion with sentinel lymph node biopsy, and one under-
went an excision biopsy only. Five patients received
adjuvant chemotherapy and one, neoadjuvant chemo-
therapy. The stages were I for five, II for one, III for four,
and unknown for one patient. Five underwent adjuvant
endocrine therapy and two, radiation therapy. One ex-
perienced post-operative bleeding. After 30 months
median follow-up, two have died.
Figure 1 shows stage-specific survival of 1,722 breast
cancer patients who underwent breast surgery between
1999 and 2011 at our hospital. Five-year overall survival
was 92.6%. Five-year survival for each stage was 97.7%
for stage I, 92.9% for stage II, 78.6% for stage III, and
49.9% for stage IV. In our study, the median follow-up
period for PTBC patients was 49 months (range: 8–146
months) and two of the 11 PTBC patients died, after 30
and 95 months of follow-up. Cumulative stage-specific





- - Alive 127
- - Alive 119
CAF(×6) Bone, lung Dead 95
- - Alive 146
- - Alive 101
CMF(×6) + AT(×4) Bone, lung, liver Dead 30
AC(×4) + T(×4) - Alive 49
AC(×4) - Alive 8
- - Alive 37
- - Alive 28
AC(×4) - Alive 17
astectomy;WE: wide excision.
Figure 1 Cumulative stage-specific survival of general population for breast cancer patients. Five-year survival for each stage was 97.7%
for stage I, 92.9% for stage II, 78.6% for stage III, and 49.9% for stage IV.




Stage I 101.0 (28–127) 71.0 (6–163) 0.690
Stage II 8.0 (8) 77.0 (3–163) 0.766
Stage III 39.5 (17–95) 70.0 (8–161) 0.213
aData are median months of survival with range in parentheses.
PTBC:post-transplant breast cancer.
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Although based on a small number of cases, the 5-year
survival for expected stage III-specific survival was
66.7% and no significant statistical difference was seen
compared to that of the general population of breast
cancer patients (P = 0.213).
Discussion
Patients undergoing kidney transplantation have a higher
risk of developing cancer as a result of immunosuppres-
sive treatment [1,3,6]. Thus, there is the possibility that
the population of breast cancer sufferers after kidney
transplantation will increase. This is the first report to
describe the characteristics of PTBC and to compare the
incidence of breast cancer in PTBC patients with that in
the general population.
Few reports have focused on breast cancer in the kid-
ney transplant population. Vachtova et al. [8] reported
PTBC without a reduction in the dose of immunosup-
pressive agent. However, this was a case report and one
experience does not explain all patients. Popov et al. [5]
and Veroux et al. [9] also reported one PTBC patient;
however, they did not focus on the nature of the breast
cancer and no description of the disease was provided.
Thus, no comparison with the general population was
made.
For treatingPTM, adjustment of the immunosuppres-
sant agent(s) must be considered. The management of
immunosuppression is also an area of concern because
few data are available to guide decisions. When surgeryis needed, dialysis access should be considered [10].
Renal graft function should be considered before chemo-
therapy. Among chemoagents, paclitaxel is an important
treatment option in patients with impaired renal graft
function [11]. There are few data regarding radiation or
hormonal therapy.
A large cohort-based study reported that 5-year net
survival was 84% in the US and 81% in Europe [12], but
this was age-standardized net survival. Women had a
5-year overall survival (OS) of 94% for stage 0, 90% for
stage I, 82% for stage II, 56.9% for stage III, and 19% for
stage IV [13]. In our study, median follow-up was 68
months, and two of the 11 PTBC patients died, after 30
and 95 months, of follow-up. For stage III patients, the
probability of surviving was approximately 66.7% at 5
years after diagnosis, comparable to that reported by
Greif et al. [13].
The younger age of PTBC patients in our study is
probably due to the small number of patients. When
more patients are evaluated, the age of PTBC patients
might increase. This is because the majority of breast
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highest incidence rate occurring between the ages of 70
and 75 years [14].
Agraharkar et al. [15] found that the relative risk
of breast cancer in a post-transplant population was
approximately 0.7 compared with that of the general
population. This is consistent with our findings. Also,
Buell et al. [16] demonstrated that immunosuppression
may not increase the incidence, but may increase the
biological aggressiveness of breast cancer. However, no
adjustment of immunosuppression was made in our 11
patients and overall survival was comparable to that of
general breast cancer patients.
The management of immunosuppression is an area
of concern when a cancer is diagnosed. The overall
amount of immunosuppression is a factor that may
lead to an increased incidence of malignancies after
renal transplantation [17]. Decreased or cessation of
immunosuppression has been associated with remis-
sion of lymphoproliferative processes. However, data
forthe therapeutic benefit of reducing immunosup-
pression in patients with solid tumors is anecdotal
[10]. Moreover, in a previous report by Marcen et al.
[18], cyclosporine therapy was not a risk factor for
any type of malignancy.
This study has some limitations. First, the small num-
bers cannot provide a proxy for the whole PTBC popula-
tion. Second, the median follow-up for PTBC was short.
This was due to the fact that most PTM is reported late
(median, 134 months) after transplantation. Finally, this
was a retrospective study and several confounding factors
were not considered.
However, this study is useful because it is a rare
study on the prognosis of breast cancer patients after
kidney transplantation. To our knowledge, there has
been no previous research on the prognosis of PTBC
patients. Also, we recommend that modifying dose of
immunosuppressant after transplantation may not be
necessary with regard to the breast cancer.
Conclusion
In conclusion, PTBC patients did not exhibit a poorer
prognosis than the general breast cancer population.
Transplant physicians should screen post-transplant
patients to identify cancers at an early stage. With regard
to PTBC, the best approach is a combination of breast
surgery, transplant surgery, and nephrology.
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